The Resistance Mechanism of ICI to EGFR and the Improvement Strategies
DOI:
https://doi.org/10.61173/wgpgx058Keywords:
- Lung cancer, immune checkpoint inhibitors (ICI), EGFR mutant type, resistance mechanism, thera-peutic efficacy differenceAbstract
Lung cancer is the leading cause of cancer-related deaths worldwide, among which non-small cell lung cancer (NSCLC) is the most common pathological subtype. Immune checkpoint inhibitors (ICIs) significantly improve the survival prognosis of patients with advanced lung cancer and enhance their quality of life by targeting molecules such as PD-1/PD-L1. However, the efficacy of ICI varies significantly. Due to the presence of EGFR mutant patients (over 50%) in the NSCLC population, these patients are insensitive to PD-L1 ICI immunosuppressive agents, resulting in limitations of PD-L1 ICI therapy. Therefore, it is necessary to systematically review the current application status, resistance mechanisms, and biomarker optimization strategies of ICI in EGFR mutant patients. This article summarizes the efficacy differences of ICI in different EGFR mutant subtypes, discusses the resistance mechanisms of ICI, and points out the optimization direction of ICI for the treatment of EGFR mutant-type lung cancer. Finally, it is found that although PD-L1 is highly expressed in EGFR mutant patients, they still have resistance; the factors of resistance include intrinsic factors and microenvironment factors; neoadjuvant immunotherapy (such as IMpower130) provides prospects for ICI treatment, but the biomarkers need to be further optimized. In conclusion, ICI has provided breakthrough progress in the treatment of EGFR-type lung cancer, but it still needs to solve the resistance problems and limitations in treatment. This article, through reviewing the above content, provides a reference for the precise decision-making and future research directions of EGFR mutant-type lung cancer treatment.
References
[1] J. F. Gainor et al., “EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer,” J. Clin. Oncol., vol. 34, pp. 2980–2987, 2016.
[2] L. Horn et al., “First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer,” N. Engl. J. Med., vol. 379, pp. 2220–2229, 2018. Dean&Francis ISSN 2959-409X
[3] P. Sharma, S. Hu-Lieskovan, J. A. Wargo, and A. Ribas, “Primary, adaptive, and acquired resistance to cancer immunotherapy,” Cell, vol. 168, no. 4, pp. 707–723, Feb. 2017.
[4] G. P. Dunn, A. T. Bruce, K. C. F. Sheehan et al., “A critical function for type I interferons in cancer immunoediting,” Nat. Immunol., vol. 6, no. 7, pp. 722–729, 2005.
[5] D. S. Shin and A. Ribas, “The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next?” Curr. Opin. Immunol., vol. 33, pp. 23–35, 2015.
[6] R. S. Herbst et al., “Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial,” Lancet, vol. 387, no. 10027, pp. 1540–1550, Apr. 2016.
[7] K. J. Lastwika, W. Wilson 3rd, Q. K. Li et al., “Control of PD-L1 expression by oncogenic activation of the AKT–mTOR pathway in non–small cell lung cancer,” Cancer Res., vol. 76, no. 2, pp. 227–238, 2016.
[8] L. Li, G. Lu, Y. Liu et al., “Low infiltration of CD8 PD- L1+ T cells and M2 macrophages predicts improved clinical outcomes after immune checkpoint inhibitor therapy in nonsmall cell lung carcinoma,” Front. Oncol., vol. 11, 658690, 2021.
[9] C. Y. Ock, B. Keam, S. Kim et al., “Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration,” Clin. Cancer Res., vol. 22, no. 9, pp. 2261–2270, 2016.
[10] M. Reck, D. Rodriguez-Abreu, A. G. Robinson et al., “Pembrolizumab versus chemotherapy for PD-L1-positive nonsmall-cell lung cancer,” N. Engl. J. Med., vol. 375, no. 19, pp. 1823–1833, 2016.
[11] T. S. K. Mok, Y. L. Wu, I. Kudaba et al., “Pembrolizumab versus chemotherapy for previously untreated, PD-L1- expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial,” Lancet, vol. 393, no. 10183, pp. 1819–1830, 2019.
[12] L. Paz-Ares, A. Luft, D. Vicente et al., “Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer,” N. Engl. J. Med., vol. 379, no. 21, pp. 2040–2051, 2018.
[13] J. Zheng, L. Tian, P. Zhao et al., “Research progress on biomarkers related to the efficacy of immunotherapy for nonsmall cell lung cancer,” Cancer Prevention and Treatment, vol. 51, no. 2, pp. 127–133, 2024.
[14] M. De Simone, A. Arrigoni, G. Rossetti et al., “Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells,” Immunity, vol. 45, no. 5, pp. 1135–1147, 2016.
[15] J. Koh, J. Y. Hur, K. Y. Lee et al., “Regulatory (FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer,” Sci. Rep., vol. 10, no. 1, 18994, 2020.
[16] D. de Miguel-Perez, A. Russo, M. Gunasekaran et al., “Baseline extracellular vesicle TGF-beta is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer,” Cancer, vol. 129, no. 4, pp. 521–530, 2023.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
